The importance of breastfeeding is well recognised with benefits for both the mother and infant. Despite these benefits, women often cease breastfeeding prematurely after experiencing common problems such as breast and nipple pain or low breast milk supply in the early weeks of breastfeeding. Some mothers stop breastfeeding while taking medications to treat these conditions because of unfounded concern or inappropriate advice from healthcare providers. Most of these conditions can be managed without the need to stop breastfeeding. This review provides pharmacists with an understanding of common breastfeeding problems and outlines evidence-based pharmacological management strategies for women experiencing these complications. All health professionals need to support mothers to continue breastfeeding for as long as they desire, and pharmacists have a unique role and a clear responsibility to provide up-to-date, evidence-based information to empower breastfeeding mothers in their decision making to ensure breastfeeding is not stopped without good reason.
INTRODUCTION
The National Health and Medical Research Council (NHMRC) recommends exclusive breastfeeding until 6 months of age, and for breastfeeding to continue alongside complementary food until 12 months of age and then for as long as the mother and the child desire. 1 This recommendation ensures newborns and infants are provided optimal nutrition to protect against infections 2,3 and lower the risk of asthma and wheeze, [4] [5] [6] and obesity and chronic diseases later in life. 7 It also provides mothers with positive outcomes, such as reducing the risk of certain cancers, osteoporosis and type 2 diabetes mellitus. 8 Despite these recommendations and recognised benefits, women often cease breastfeeding prematurely after experiencing common problems such as breast and nipple pain, low breast milk supply or maternal or infant illness. 9 Further, although only a limited number of medications are contraindicated during lactation, previous research shows that some mothers stop breastfeeding while taking medications because of unfounded concern or inappropriate advice from healthcare providers. 10, 11 A 2010 survey conducted in Australia evaluated factors governing general practitioners' (GPs) decision making when prescribing medicines to a breastfeeding mother and showed that cessation of breastfeeding was sometimes recommended unnecessarily. 10 Pharmacists have a unique role and a clear responsibility to provide up-to-date, evidence-based information to empower breastfeeding mothers in their decision making to ensure breastfeeding is not stopped without good reason. This review summarises the current evidence for the role of medications in a range of conditions encountered by breastfeeding mothers.
BREAST AND NIPPLE PAIN
Persistent breast or nipple pain is one of the reasons for early weaning, so diagnosing and managing the underlying causes are important to support breastfeeding. In practice, there may be more than one source of breast or nipple pain, making this difficult. All clinical features, medical history and pathology results should be reviewed on an individual basis.
Mastitis
Mastitis is an inflammation of the breast that may or may not involve a bacterial infection and is characterised by redness and pain of the breast, often accompanied by fever, chills and flu-like symptoms. Studies have reported that up to one in five lactating women experience mastitis. Although mastitis may occur at any stage of lactation, most cases occur in the first 12 weeks postpartum. Almost 10% of women experience a recurrent episode and up to 3% will develop an abscess, often requiring admission to hospital. 13, 14 Factors associated with the development of mastitis include nipple damage, attachment problems, incomplete emptying of the breasts, illness in the mother or baby, milk oversupply and expressing milk several times a day. [15] [16] [17] Laboratory investigations are not routinely undertaken on initial presentation. Breast milk samples and sensitivity testing are generally only performed in severe, recurrent or unusual cases, if there is no response to antibiotics within two days, or if there is an allergy to usual therapeutic antibiotics. 18 Management of mastitis includes a number of steps to effect milk removal, such as feeding more frequently, improving infant attachment and position, massaging the breast during feeding and expressing after feeding to augment milk drainage. Supportive measures such as rest, adequate fluids, application of heat (with heat packs or warm showers) and nutrition are also important. 19 Breastfeeding or expressing from the infected breast is continued because there is no evidence of harm to the infant and it reduces the risk of an abscess developing. 20 Simple analgesia with regular oral paracetamol may assist with pain and fever. Non-steroidal anti-inflammatory drugs (NSAIDs), such as ibuprofen, relieve inflammatory symptoms associated with mastitis and may assist with the let-down reflex. Ibuprofen has a very low relative infant dose (RID) of <0.38% and is considered compatible with breastfeeding.
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Although a Cochrane review of treatment for mastitis found insufficient evidence to confirm the effectiveness of antibiotics, 22 symptoms persisting for 24 h or longer require antibiotic treatment to prevent abscess formation. 18, 20, 23 Staphylococcus aureus is the most common causative organism of mastitis and the recommended first-line treatment is with a narrow-spectrum, beta-lactamase resistant penicillin such as flucloxacillin or dicloxacillin at a dose of 500 mg orally four times a day. Cefalexin 500 mg orally four times a day is recommended for women with hypersensitivity to penicillins. In patients with immediate penicillin hypersensitivity, clindamycin 450 mg orally every 8 h is recommended. 24 The duration of antibiotic treatment is controversial, with an absence of clinical trials to guide practice. Although the Australian Therapeutic Guidelines recommend treatment for at least 5 days, 24 some clinicians recommend longer courses of 10-14 days to prevent recurrence or the formation of an abscess. 20 Methicillin-resistant S. aureus (MRSA) is now common in many parts of Australia, and its presence needs to be considered in recurrent cases or where there is no improvement after 48 h of first-line antibiotic therapy. 25 Treatment should be guided by breast milk culture results and sensitivities.
If severe cellulitis develops, intravenous (IV) therapy should be commenced with flucloxacillin 2 g every 6 h, or cefazolin 2 g every 8 h for women hypersensitive to penicillins. If there is an immediate hypersensitivity, then clindamycin 600 mg every 8 h is the preferred option.
24 Therapy is usually continued for 48-72 h before changing to the oral regimes outlined above. Total treatment duration (IV and oral) of up to 2 weeks is recommended.
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Mothers need be reassured that despite the conservative recommendations contained in consumer product information, relatively small amounts of the treatment antibiotics pass into the breast milk (RIDs 0.4-1.8%) and the amount ingested by infants is unlikely to have harmful effects. 23, 24 Infants may develop diarrhoea, which is usually temporary and resolves on completion of the antibiotic course. Vomiting, skin rash or thrush are also potential adverse effects.
Nipple Vasospasm
Nipple vasospasm, or Raynaud's phenomenon of the nipple, is a condition characterised by vasospasm of the arterioles causing intermittent reduced blood flow to the area. 26, 27 Typically, colour changes of the nipple occur, beginning with blanching, secondary to vasoconstriction and ischemia, followed by blue colouring and an eventual red/purple colour from reflex vasodilation. 12, 16 The intermittent ischaemia can cause acute shooting or burning breast pain. Risk factors include a history of connective tissue disorders or prior diagnosis of Raynaud's phenomenon. 12, 28 Due to its association with Raynaud's phenomenon, the principles of nipple vasospasm management are similar. Primary management includes reducing emotional stress, applying warm compresses after breastfeeding and avoidance of cold and aggravating factors, such as smoking, caffeine, beta-blockers and sympathetic agonists. 12, 26, 29, 30 If these techniques prove ineffective, medication use may be considered. Calcium channel blockers (CCBs) have been shown to reduce the frequency of attacks due to their vasodilatory effects, and sustained release (SR) formulations are currently first-line therapy for nipple vasospasm. 12, 27, 28 In a study of 22 women diagnosed with Raynaud's phenomenon of the nipple, 15 (68%) were prescribed nifedipine along with non-pharmacological recommendations. 27 Nifedipine was discontinued in three women (20%) due to side effects including dizziness, headaches, decreased blood pressure and light headedness. Of those continuing with nifedipine, 10 (83%) reported a decrease or resolution of pain. 27 A trial of nifedipine SR 20 mg daily, increasing, if required, to a maximum of 60 mg daily, should be undertaken for at least 2 weeks. A longer duration may be required if symptoms persist. 12, 19, 27 Most women respond to 20 to 30 mg slow release daily. 19 If the mother experiences common adverse effects from nifedipine, consider a trial of low-dose therapy at 10 mg/day nifedipine. 27 The low RID, high protein binding and lack of adverse effects reported in exposed infants demonstrate nifedipine's compatibility with breastfeeding. 31 
Nipple Thrush
Nipple thrush has been defined as a burning nipple pain that may radiate to the breast or back, with no breast erythema or systemic symptoms of infection. 11, 32, 33 The pain is usually out of proportion with clinical findings and not relieved by expressing (as for mastitis) or heat (as for nipple vasospasm). 12, 34 The nipple can be pink, shiny or flaky, and the infant may have symptoms of oral thrush or a fungal nappy rash. Nipple thrush usually results from nipple trauma and, without early diagnosis and management, may lead to early weaning. Although some studies have found nipple thrush to be commonly associated with Candida spp. colonisation of the nipple, breast milk or infant's mouth, 11, 33 others have found no correlation. 12, 32, 35 Thus, milk samples cannot be relied upon to support diagnosis. 36 Risk factors of nipple thrush include a predisposition to Candida infections, recent use of antibiotics and thrush of the infant's mouth or nappy area.
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First-line management of nipple thrush is application of miconazole 2% cream to the nipples after each feed. If there is deep, aching breast pain or a history of persistent thrush, a course of oral fluconazole may be considered. There is currently no consensus for the dosing of fluconazole. An open-label non-controlled Australian study demonstrated reasonable efficacy of fluconazole when administered at a dose of 150 mg every second day until breast pain resolves. 36 In contrast, the Academy of Breastfeeding Medicine (ABM) suggests an initial dose of 200 mg, followed by 100 mg daily for 7-10 days. 12 Because fluconazole is not listed on the Australian Pharmaceutical Benefits Scheme, product availability and cost need to be considered. It is important to conduct a full review of concurrent medications if fluconazole is required, because fluconazole interacts with many medications due to its significant inhibition of cytochrome P450 enzymes and prolonging effect on the QTc interval. Notably, fluconazole should be used with extreme caution in patients also taking domperidone during lactation. 12, 37 Although fluconazole has a comparatively high RID between 16 and 22%, no serious adverse effects have been reported in breastfed infants. The amount received via breast milk is not sufficient to treat oral thrush in the infant, and it is considered safe to use while breastfeeding. 36, 38 When treating nipple or breast thrush, it is important to also treat the infant at the same time in order to prevent reinfection. First-line management is nystatin oral suspension 1 mL four times a day or miconazole oral gel, ¼ teaspoon four times a day. The gel presents a choking hazard to infants under 6 months of age, so it needs to be applied to the inside of the cheeks and over the tongue with a clean finger or cotton bud. 12 
BREAST MILK SUPPLY Managing Low Milk Supply
Because breast milk provides optimal nutrition for newborns and infants, the importance of establishing an adequate milk supply in the early postpartum period is vital. This is critical for mothers of very preterm infants, because human breast milk not only helps to reduce morbidities associated with premature birth, but also improves neurodevelopmental outcomes for these infants. 39 Establishing and then maintaining a milk volume to meet the nutritional needs of an infant can be challenging. Primary non-pharmacological strategies, such as frequent and effective breast emptying and correct infant positioning and attachment, need to be optimised first. 40, 41 If this is not sufficient, and a mother is still struggling, then pharmacological intervention with medications known as galactagogues may be considered to augment lactation. Domperidone and metoclopramide are the most commonly used galactagogues, and both are dopamine receptor antagonists that increase prolactin secretion. 41, 42 Although prolactin is a key regulator of milk production in the early stages of lactation, once lactation is established milk production is primarily driven by infant demand and removal of milk from the breast.
Metoclopramide
Trial results regarding the capacity of metoclopramide to increase milk supply have been varied, with some studies reporting no change in milk volumes and other, older studies reporting significant increases in milk yield. 43 A prospective randomised controlled study in 80 mothers of preterm infants with documented low milk supply showed that metoclopramide dosed at 10 mg three times daily, given for 10 days, had a similar increase in milk volume (93.7%) to domperidone (96.3%). 41 Breastfed infants receive between 4.7 and 14.3% of the maternal weight-adjusted dosage of metoclopramide. 44 Although adverse effects in infants have not been reported, metoclopramide, unlike domperidone, is known to cross the blood-brain barrier and is to be avoided in women with a history of anxiety and depression. 41, 43 In 2015, the Australian Therapeutic Goods Administration completed a review of metoclopramide and introduced changes for both the dose and duration to minimise the risk of potentially serious neurological adverse events. The recommended maximum treatment duration was changed to 5 days with a maximum daily dose of 30 mg and use in children under 1 year of age was contraindicated. 45 The potential for centrally based side effects in the mother and the regulatory changes have prompted clinicians to use domperidone as the preferred galactagogue.
Domperidone
A recent systematic review of domperidone for increasing breast milk supply found an increase in volume of 88 mL/day in mothers of preterm infants with confirmed low milk supply. 46 That review included results from the EMPOWER trial, which demonstrated similar improvements in milk supply among women receiving either 2 or 4 weeks of domperidone, suggesting shorter durations of treatment may be sufficient. 47 Currently, no studies have examined the long-term use of domperidone beyond 6 weeks, 48 and it remains unclear whether ongoing use is required to sustain the increase in breast milk volume.
There have been safety concerns with the use of domperidone because of its potential to prolong the QTc interval. Domperidone has been associated with an increased risk of ventricular arrhythmias and sudden cardiac death, primarily among older, unwell adults with other comorbidities. 49, 50 In 2014, the European Medicines Agency additionally identified a higher risk of adverse cardiac events in those receiving doses above 30 mg daily and with the concomitant use of drugs that prolong the QTc interval or cytochrome P450 3A4 (CYP3A4) inhibitors, such as azole antifungals and macrolide antibiotics. 51 The relevance in younger women with no other risk factors remains uncertain. A large Canadian database study of 45 518 women exposed to domperidone in the postpartum period found a possible association between domperidone exposure and ventricular arrhythmia (adjusted hazard ratio 1.69; 95% confidence interval 0.48-5.96). 52 However, all cases occurred in women who had a previous history of ventricular arrhythmia. 53 To mitigate the potential risks identified in these recent studies, appropriate screening of mothers for a past history of cardiac arrhythmias, concurrent use of medications that may prolong the QTc interval or inhibit the metabolism of domperidone needs to be considered before commencing domperidone. Although not based on direct evidence, the ABM guidelines suggest performing an electrocardiogram on women of concern before the commencement of the medication and then at 48 h. If there is prolongation of the QTc interval, the medication may be ceased. 43 Despite concerns regarding the potential of prolonged QTc syndrome and sudden cardiac death, the risks associated with domperidone use among healthy lactating women with no history of cardiac arrhythmia appear extremely small. 43, 46 Based on the current literature, domperidone is the galactagogue of choice, at a dose of 10 mg three times daily, with no clear evidence to support a higher dose. 46 Treatment durations range from 7 days to 6 weeks, although longer durations are seen in practice. There is an absence of evidence for one approach over another. 54 Treatment should be tailored to the individual, based on identified risk factors or causes of low milk supply. Tapering of the dose is often recommended to minimise disruption to milk supply, although there is no direct evidence to support this practice.
With recommended maternal dosages the concentration of domperidone in breast milk is <1 lg/L, or approximately 0.01% of the mother's weight-adjusted dose, so the risk of infant toxicity appears negligible. 55 
Lactation Suppression
There are situations when women may wish or need to suppress lactation either before lactation is established or after breastfeeding for a period of time. Reasons include a late miscarriage, stillbirth, if an infant dies while still being breastfed, if the mother has a severe illness or is being treated with medications contraindicated in breastfeeding or she chooses to formula feed. 56 Initial management includes the use of cold packs and mild analgesics to alleviate discomfort, expression to relieve engorgement and avoiding breast stimulation as much as possible. If medications are deemed necessary, cabergoline is the recommended dopamine agonist. 57, 58 Bromocriptine is no longer considered appropriate for lactation inhibition because of its potentially serious side effects, including cardiovascular disorders, predominantly ischaemic events, neurological and psychiatric disorders. [58] [59] [60] [61] There has been one report of cabergoline triggering an episode of mania in a patient with a pre-existing psychotic illness, but none in well women.
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A single dose of 1 mg cabergoline produces a prolactin-lowering effect, usually within 3 h of administration, which may persist for at least 21 days in puerperal women. Cabergoline should be taken as soon as possible, and preferably within the first 24 h after delivery, to maximise response. 62 Although there are no published studies on the use of cabergoline for the suppression of established lactation, a dose schedule of 0.25 mg twice daily for 2 days has been suggested as the most appropriate for this indication. 58 
CONCLUSION
Breastfeeding mothers often experience nipple or breast pain during lactation or have difficulty with breast milk supply issues that can lead to early discontinuation of breastfeeding. Through an understanding of common lactation problems and their appropriate pharmacological management, pharmacists are in the ideal position to support optimal breastfeeding outcomes through the provision of evidence-based information and reassurance on the safety of medications while breastfeeding.
